. Human (a) and murine (b) AML cells harboring wild type or ITD, TKD, or dual mutations of FLT3 were treated with indicated concentrations of selinexor for 72 h, Absolute viable cell number was counted using the Trypan blue dye exclusion method and relative percentage of anti-proliferative effect was assessed by compared with DMSO control group. S3 Fig. S3 . Human AML cells MOLM13, MV4-11 (Harboring FLT3ITD mutations) and THP-1, Kasumi-1 (FLT3 wild type) cells were treated with indicated concentrations of selinexor for 72 h, Apoptosis induction was assessed by measuring annexin V positivity using flow cytometry.
S4

Fig. S4
. Baf3-ITD, Baf3-ITD+842 and Baf3-ITD+D835Y cells were exposed in indicated concentrations of selinexor for 24 h. Total RNA was isolated with Trizol as directed by the manufacturer and reverse transcribed and qPCR were performed as described in our previous publication [Zhang, W, et al. Mol Cancer Ther. 2014; 13:1848-59] . mRNA level of human FLT3 Hs00174690_m1. was assessed by qPCR. Results were analyzed using RQ Manager 1.2.1 software with 18S as housekeeping gene. Fig. S7 . Baf3-ITD and Baf3-ITD+842 cells were exposed in varying concentrations of selinexor for indicated time points and the cells were collected for lysis. Phosphorylated level of correlated proteins were assessed using immunoblotting. GAPDH was as loading control. . Human leukemia cell lines MOLM13 and MV4-11 were exposed in indicated concentrations of selinexor for 24 h, and the cells were collected for lysis. Phosphorylated level of correlated proteins were assessed using immunoblotting. GAPDH was as loading control. 
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